Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults

Neurology

Volumn 89, Issue 12, 2017, Pages 1251-1255

  Li, Ge ^a   Mayer, Cynthia L ^a   Morelli, Daniel ^b   Millard, Steven P ^a   Raskind, Wendy H ^b   Petrie, Eric C ^c   Cherrier, Monique ^a   Fagan, Anne M ^c   Raskind, Murray A ^a,c   Peskind, Elaine R ^a  

^a Veterans Administration Northwest Network   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOPROTEIN; PHOSPHORYLATED TAU 181 PROTEIN; PLACEBO; SIMVASTATIN; TAU PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEPTIDE FRAGMENT;

ADULT; ALZHEIMER DISEASE; ANALYSIS OF COVARIANCE; ARTICLE; CEREBROSPINAL FLUID; CHOLESTEROL BLOOD LEVEL; CLINICAL EXAMINATION; COGNITION; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG PROTEIN BINDING; HUMAN; HYPERCHOLESTEROLEMIA; MEASUREMENT; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; BLOOD; FEMALE; FOLLOW UP; MALE; MIDDLE AGED;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; CHOLESTEROL, LDL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIDE FRAGMENTS; SIMVASTATIN; TAU PROTEINS;

EID: 85031041857     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000004392     Document Type: Article

References (10)

1. Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: I: Review of epidemiological and preclinical studies. Arch Neurol 2011; 68:1239-1244.
2. Leduc V, De Beaumont L, Theroux L, et al. HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study. Mol Psychiatry 2015;20:867-873.
3. Li G, Larson EB, Sonnen JA, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2007;69:878-885.
4. Sano M, Bell KL, Galasko D, et al. A randomized, doubleblind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011;77:556-563.
5. Riekse RG, Li G, Petrie EC, et al. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis 2006;10:399-406.
6. Fan QW, Yu W, Senda T, Yanagisawa K, Michikawa M. Cholesterol-dependent modulation of tau phosphorylation in cultured neurons. J Neurochem 2001;76:391-400.
7. Glockner F, Meske V, Lutjohann D, Ohm TG. Dietary cholesterol and its effect on tau protein: A study in apolipoprotein E-deficient and P301L human tau mice. J Neuropathol Exp Neurol 2011;70:292-301.
8. Lu F, Li X, Suo AQ, Zhang JW. Inhibition of tau hyperphosphorylation and beta amyloid production in rat brain by oral administration of atorvastatin. Chin Med J (Engl) 2010;123:1864-1870.
9. Popp J, Meichsner S, Kolsch H, et al. Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease. Biochem Pharmacol 2013;86: 37-42.
10. Carlsson CM, Gleason CE, Hess TM, et al. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. J Alzheimers Dis 2008;13:187-197.